Styrelsen och verkställande direktören för Phase Holographic Imaging PHI AB (publ), organisationsnummer 556542-7811 och med säte i Lund, avger härmed årsredovisning för räkenskapsåret 1 maj 2018 – 30 april 2019.
Strong sales growth for the 3rd consecutive quarter. Recent advancements in regenerative medicine create additional growth potential in clinical applications for the company.
The strategic shift of sales and marketing continues to prove itself. Despite being a “slow summer quarter”, sales during May – July surpassed sales during any previous quarter.
PHI and RegenMed Development Organization have entered a partnership to advance large-scale biomanufacturing of cell-based therapies.
